Find a Viewpoint

Antimicrobial Viewpoints are articles in which experts in different areas of antimicrobial resistance share their knowledge and opinions about the current status and the future challenges of this field. You can read our editorial and ethics policies for these articles here

<br>COVID-19 and why tackling the silent crisis of drug-resistant infections matters more than ever</br><em> – by Manica Balasegaram</em>
2 April 2020

COVID-19 and why tackling the silent crisis of drug-resistant infections matters more than ever – by Manica Balasegaram

more
<br>The antibiotics marketplace collapse: It’s just math, and it’s a solvable equation</br><em> – by Ryan Cirz and Kevin Krause</em>
17 March 2020

The antibiotics marketplace collapse: It’s just math, and it’s a solvable equation – by Ryan Cirz and Kevin Krause

more
<br>Diagnostics to safeguard new and current antibiotics for gonorrhoea</br><em> – by Cassandra Kelly-Cirino and Cecilia Ferreyra</em>
22 January 2020

Diagnostics to safeguard new and current antibiotics for gonorrhoea – by Cassandra Kelly-Cirino and Cecilia Ferreyra

more
<br>On fireworks and finding ways to address drug-resistance in low- and middle-income countries</br><em> – by Ramanan Laxminarayan</em>
16 December 2019

On fireworks and finding ways to address drug-resistance in low- and middle-income countries – by Ramanan Laxminarayan

more
<br>Bringing antimicrobial research and development to Africa – the time is now</br><em> – by Greg Basarab and Kelly Chibale</em>
3 December 2019

Bringing antimicrobial research and development to Africa – the time is now – by Greg Basarab and Kelly Chibale

more
<br>Talking about the ‘antibiotic apocalypse’ won’t encourage public action – here’s why</br><em> – by Tim Jinks</em>
19 November 2019

Talking about the ‘antibiotic apocalypse’ won’t encourage public action – here’s why – by Tim Jinks

more

Share

FacebookTwitterLinkedInEmail
✕

Newsletter

Subscribe to our newsletter to stay up-to-date about our webinars, conferences and other activities.



View previous newsletter

Go to Top